The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Applebaum, Mark
PropertyValue
overview Mark Applebaum, MD, is an expert in pediatric cancers and blood diseases. He has a special interest in the treatment of neuroblastoma, sarcomas and solid tumors. Dr. Applebaum is a translational physician-scientist working on harnessing genomics and “big data” to advance treatments for children with neuroblastoma. He bridges the fields of epigenetics, genomics, and cancer biology to identify idenitfy novel risk classifiers and therapeutic targets. Dr. Applebaum focuses his research on how specific epigenetic marks can identify patients with aggressive neuroblastoma that may benefit from alternatives to standard therapy. His laboratory is also identifying how the low-oxygen environment of tumors makes cancer cells more resistant to standard therapies by inducing changes in these same epigenetic marks. Identifying the genes and cellular pathways responsible for these changes may ultimately open new avenues for novel therapeutic options. Dr. Applebaum's research is supported by the National Cancer Institute and the University of Chicago Cancer Center Auxiliary Board. He has received funding from the Conquer Cancer Foundation, Cancer Research Foundation, and the Bear Necessities Foundation. He is the recipient of numerous awards from the American Society of Clinical Oncology, the American Association of Cancer Researchers, and the Advances in Neuroblastoma Research Association.
One or more keywords matched the following items that are connected to Applebaum, Mark
Item TypeName
Concept Neuroblastoma
Academic Article Second malignancies in patients with neuroblastoma: the effects of risk-based therapy.
Academic Article Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
Academic Article Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.
Academic Article Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.
Academic Article Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.
Academic Article Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids.
Grant Elucidating transcription regulation by epigenetics in neuroblastoma
Academic Article Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.
Academic Article Emerging and investigational therapies for neuroblastoma.
Academic Article Genetic Predisposition to Neuroblastoma.
Academic Article Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.
Academic Article 5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype.
Academic Article 5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma.
Academic Article Pleuroparenchymal fibroelastosis in an 8-year old treated for neuroblastoma.
Academic Article Nervous system: Embryonal tumors: Neuroblastoma.
Academic Article Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.
Academic Article Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients.
Academic Article Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma.
Academic Article Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group.
Grant Circulating Tumor Biomarkers: New Paradigms for Management of Neuroblastoma
Academic Article Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.
Grant Liquid biopsy approaches to inform neuroblastoma prognosis and disease monitoring
Academic Article MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia.
Academic Article 5-hydroxymethylcytosine profiling of cell-free DNA identifies bivalent genes that are prognostic of survival in high-risk neuroblastoma.
Academic Article Histotripsy induces apoptosis and reduces hypoxia in a neuroblastoma xenograft model.
Academic Article T-cell inflammation is prognostic of survival in patients with high-risk neuroblastoma enriched for an adrenergic signature.
Academic Article Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.
Academic Article Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.
Academic Article Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades.
Academic Article 5-Hydroxymethylcytosine Profiling of Cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma.
Academic Article Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation.
Grant Liquid biopsy approaches to inform neuroblastoma prognosis and disease monitoring
Academic Article Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures.
Search Criteria
  • Neuroblastoma